Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study

James W Albers, William H Herman, Rodica Pop-Busui, Eva L Feldman, Catherine L Martin, Patricia A Cleary, Barbara H Waberski, John M Lachin, Diabetes Control and Complications Trial /Epidemiology of Diabetes Interventions and Complications Research Group, James W Albers, William H Herman, Rodica Pop-Busui, Eva L Feldman, Catherine L Martin, Patricia A Cleary, Barbara H Waberski, John M Lachin, Diabetes Control and Complications Trial /Epidemiology of Diabetes Interventions and Complications Research Group

Abstract

Objective: To evaluate the impact of former intensive versus conventional insulin treatment on neuropathy in Diabetes Control and Complications Trial (DCCT) intensive and conventional treatment subjects with type 1 diabetes 13-14 years after DCCT closeout, during which time the two groups had achieved similar A1C levels.

Research design and methods: Clinical and nerve conduction studies (NCSs) performed during the DCCT were repeated during the Epidemiology of Diabetes Interventions and Complications (EDIC) study by examiners masked to treatment status on 603 former intensive and 583 former conventional treatment subjects. Clinical neuropathy was defined by symptoms, sensory signs, or reflex changes consistent with distal polyneuropathy and confirmed with NCS abnormalities involving two or more nerves among the median, peroneal, and sural nerves.

Results: The prevalence of neuropathy increased 13-14 years after DCCT closeout from 9 to 25% in former intensive and from 17 to 35% in former conventional treatment groups, but the difference between groups remained significant (P < 0.001), and the incidence of neuropathy remained lower among former intensive (22%) than former conventional (28%) treatment subjects (P = 0.0125). Analytic models of incident neuropathy that adjusted for differences in NCS results at DCCT closeout showed no significant risk reduction associated with former intensive treatment during follow-up (odds ratio 1.17 [95% CI 0.84-1.63]). However, a significant persistent treatment group effect was observed for several NCS measures. Longitudinal analyses of overall glycemic control showed a significant association between mean A1C and measures of incident and prevalent neuropathy.

Conclusions: The benefits of former intensive insulin treatment persisted for 13-14 years after DCCT closeout and provide evidence of a durable effect of prior intensive treatment on neuropathy.

Trial registration: ClinicalTrials.gov NCT00360893.

References

    1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977– 986
    1. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC): design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999; 22: 99– 111
    1. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563– 2569
    1. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159– 2167
    1. The Diabetes Control and Complications Trial/Epidemiology of Diabetes and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342: 381– 389
    1. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643– 2653
    1. Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, Feldman EL: the DCCT/EDIC Research Group. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006; 29: 340– 344
    1. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetic therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561– 568
    1. Diabetes Control and Complications Trial Research Group. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18: 361– 376
    1. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995; 38: 869– 880
    1. Wei LJ, Lachin JM: Two sample asymptotically distribution free tests for incomplete multivariate observations. J Am Stat Assoc 1984; 79: 653– 661
    1. Albers JW, Herman WH, Pop-Busui R, Martin CL, Cleary P, Waberski B: the DCCT/EDIC Research Group. Subclinical neuropathy among diabetes control and complications trial participants without diagnosable neuropathy at trial completion: possible predictors of incident neuropathy? Diabetes Care 2007; 290: 2159– 2167
    1. Akaike H: A new look at the statistical model identification. IEEE Trans Automatic Cont 1974; 16: 716– 723
    1. Service FJ, Daube JR, O'Brien PC, Dyck PJ: Effect of artificial pancreas treatment on peripheral nerve function in diabetes. Neurology 1981; 31: 1375– 1380
    1. Larsen SR, Sjoholm H, Hanssen KF, Sandvik L, Berg TJ, Dahl-Jorgensen K: Optimal blood glucose during 18 years preserves peripheral nerve function in patients with 30 years' duration of type 1 diabetes. Diabetes Care 2003; 26: 2400– 2404
    1. The EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341– 350
    1. Thomas PK: Diabetic peripheral neuropathies: their cost to patient and society and the value of knowledge of risk factors for development of interventions. Eur Neurol 1999; 41( Suppl 1): 35– 43
    1. The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008; 126: 1707– 1715

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe